Frontiers Research, the organisation which runs the Fairfax Neurology Centre, is working on a clinical trial to find out how to treat Frontiers patients with Parkinson’s disease with neurofeedback.
Key points:The trial, which is currently in its early stages, will involve people with Parkinsonism receiving neurofeedbacks during their hospitalisationThe study is designed to investigate the effect of neurofeedBACK on patients with Frontiers conditionsBrain scans will be taken before and after patients receive neurofeedBackBrain scans are already being used to help Parkinson’s sufferers and the general population with their conditionThe trial is set to be completed in the second half of 2019.
The trial will involve patients with a diagnosis of Parkinson’s, but it will be designed to look at a range of conditions, including Frontiers’ other Parkinson’s patients.
The aim of the trial is to see if neurofeed back can help patients who suffer from symptoms such as nausea, weakness, difficulty concentrating and dizziness, and will hopefully be able to treat some of those conditions.
It is also intended to find the best way to manage symptoms and to help patients stay off medication for longer periods of time.
The centre, which was set up in 1998, has already helped over 2,500 patients with the disease, including over 1,200 with Frontier.
However, the centre has struggled to maintain its focus in the field of Parkinsonism research.
In the last few years, the number of Frontier patients undergoing clinical trials at the centre is falling, with just one patient from the first wave of the clinical trial this year making it through to the trial.
The Parkinson’s research centre at Fairfax is set up to investigate Parkinson’s and other neurological conditions, and is working with organisations such as the Australian Institute of Neurology and the Australian Medical Association to find solutions to their challenges.
But the centre’s chairman, Dr Tim Denny, said it was vital that Frontiers continue to work on Parkinson’s.
“If we’re going to be a leader in this field we need to continue to do that,” Dr Denny said.
“We need to get on top of this.
We need to make sure we’re working on the issues of Fronties and all of the other conditions we’re trying to address.”
In the past, the Fairfax Centre has also looked at how to reduce the risks of Parkinsons.
For instance, a study at the Centre in 2016 looked at a different way of treating patients with frontiers conditions such as Parkinson’s using the neurofeed-back system known as the Mind-Body Connection.
In that study, neurofeed Back was given to Parkinson’s participants before they received a standard treatment such as anti-convulsant drugs.
However this study, which followed up on the participants over three years, was unsuccessful in reducing the number and severity of Parkinsonisms.
In a statement, Dr Dyson said that this was because it was not possible to monitor participants’ neurofeed backs during treatment.
“It was just not feasible,” he said.
However the centre says that the study was the first step towards a more permanent solution, as a clinical research trial would help to identify what the optimal treatment for Parkinson’s was.
The neurofeed system is currently used by the Australian National Parkinson’s Centre in Canberra to monitor Parkinson’s activity in people with frontier conditions.